RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by our mission to treat inflammatory and immunologic diseases. Our cutting-edge science is fully focused on developing …

RAPT Therapeutics is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and …

RAPT Therapeutics is focused on the development of therapies for patients with significant unmet needs in inflammatory and immunologic diseases. Utilizing our deep and proprietary expertise in …

Our proprietary drug discovery and development engine has identified several immune drivers that have the ability to be “tuned down” to suppress an overactive immune response in inflammatory diseases. …

Oct 27, 2025 · About RAPT Therapeutics, Inc. RAPT is a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel …

RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies October 21 | 2025

At RAPT Therapeutics, we believe in bringing our whole selves to work each day, which requires important work-life balance. We encourage all employees to rejuvenate by sharing experiences with …

Oct 21, 2025 · In addition, RAPT has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 shares of its common stock at the public offering price, less underwriting …

Sep 30, 2025 · RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights November 06, 2025 - Initiated prestIgE Phase 2b trial of ozureprubart in food allergy - Announced …

Dec 23, 2024 · RAPT Therapeutics is a clinical-stage, immunology-based therapeutics company focused on discovering, developing and commercializing therapies for patients with significant unmet …